French
DeutschSerum amyloid P component
The serum amyloid P component (SAP) is the identical serum form of the amyloid P component (AP), a 25 kDa pentameric protein first identified as the pentagonal constituent of in vivo pathological deposits called "amyloid".[5] APCS is its human gene.[6]
In amyloidosis
[edit]SAP makes up 14% of the dry mass of amyloid deposits[7] and is thought to be an important contributor to the pathogenesis of a related group of diseases called the Amyloidoses.[8] These conditions are characterised by the ordered aggregation of normal globular proteins and peptides into insoluble fibres, which disrupt tissue architecture and are associated with cell death. SAP is thought to decorate and stabilise aggregates by preventing proteolytic cleavage and hence inhibiting fibril removal via the normal protein scavenging mechanisms.[9] This association is utilised in the routine clinical diagnostic technique of SAP scintigraphy whereby radio-labelled protein is injected into patients to locate areas of amyloid deposition.[10] The SAP-amyloid association has also been identified as a possible drug target for anti-amyloid therapy, with the recent development and first stage clinical trials of a compound called CPHPC (R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxohexanoyl] pyrrolidine-2-carboxylic acid), a small molecule able to strip AP from deposits by reducing levels of circulating SAP.[11]
Structure
[edit]SAP is a member of the pentraxins family, characterised by calcium-dependent ligand binding and a distinctive flattened β-jellyroll structure similar to that of the legume lectins.[12] The name "pentraxin" is derived from the Greek words for five (penta) and berries (ragos), relating to the radial symmetry of five monomers forming a ring approximately 95 across and 35 deep. Human SAP has 51% sequence homology with C-reactive protein (CRP), a classical acute phase response plasma protein, and is a more distant relative to the "long" pentraxins such as PTX3 (a cytokine-modulated molecule) and several neuronal pentraxins. Both SAP and CRP are evolutionary conserved in all vertebrates and are also found in distant invertebrates such as the horseshoe crab (Limulus polyphemus).[13]
References
[edit]- ^ a b c GRCh38: Ensembl release 89: ENSG00000132703 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000026542 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Cathcart ES; Shirahama T; Cohen AS (1967). "Isolation and identification of a plasma component of amyloid". Biochim. Biophys. Acta. 147 (2): 392–393. doi:10.1016/0005-2795(67)90420-5.
- ^ "Entrez Gene: APCS amyloid P component, serum".
- ^ Skinner M; Pepys MB; Cohen AS; Heller LM; Lian JB (1980). Freitas, Antonio Falcão de; Glenner, George G.; Costa, Pedro Pinho e. (eds.). Amyloid and amyloidosis: proceedings of the Third International Symposium on Amyloidosis, Póvoa de Varzim, Portugal, 23–28 September 1979. Amsterdam: Excerpta Medica. pp. 384–391. ISBN 0-444-90124-8.
- ^ Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB (August 1997). "Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene". Nature Medicine. 3 (8): 855–9. doi:10.1038/9544. PMID 9256275. S2CID 19553541.
- ^ Tennent GA, Lovat LB, Pepys MB (May 1995). "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis" (PDF). Proceedings of the National Academy of Sciences of the United States of America. 92 (10): 4299–303. doi:10.1073/pnas.92.10.4299. PMC 41931. PMID 7753801.
- ^ Hawkins PN, Pepys MB (July 1995). "Imaging amyloidosis with radiolabelled SAP". European Journal of Nuclear Medicine. 22 (7): 595–9. doi:10.1007/BF01254559. PMID 7498219. S2CID 8549928.
- ^ Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (May 2002). "Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis". Nature. 417 (6886): 254–9. doi:10.1038/417254a. PMID 12015594. S2CID 733818.
- ^ Emsley J, White HE, O'Hara BP, Oliva G, Srinivasan N, Tickle IJ, Blundell TL, Pepys MB, Wood SP (January 1994). "Structure of pentameric human serum amyloid P component". Nature. 367 (6461): 338–45. doi:10.1038/367338a0. PMID 8114934. S2CID 4284282.
- ^ Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E (1997). "Amyloid P component. A critical review". Amyloid. 4 (4): 274–295. doi:10.3109/13506129709003838.
PDB gallery | |
|---|---|
|
![2a3w: Decameric structure of human serum amyloid P-component bound to Bis-1,2-{[(Z)-2-carboxy-2-methyl-1,3-dioxane]-5-yloxycarbamoyl}-ethane](/wiki/en/File:PDB_2a3w_EBI.jpg)
![2a3x: Decameric crystal structure of human serum amyloid P-component bound to Bis-1,2-{[(Z)-2carboxy- 2-methyl-1,3-dioxane]- 5-yloxycarbonyl}-piperazine](/wiki/en/File:PDB_2a3x_EBI.jpg)
![2a3y: Pentameric crystal structure of human serum amyloid P-component bound to Bis-1,2-{[(Z)-2carboxy-2-methyl-1,3-dioxane]-5-yloxycarbamoyl}-ethane.](/wiki/en/File:PDB_2a3y_EBI.jpg)